Yang Lei, Sun Zhipeng
Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, P.R. China.
Mol Clin Oncol. 2024 Sep 6;21(5):82. doi: 10.3892/mco.2024.2780. eCollection 2024 Nov.
In recent years, the incidence of liver cancer has increased annually. However, current medical treatments for liver cancer are limited, and most patients have a high risk of recurrence after surgery. Therefore, the discovery and development of novel treatment targets for liver cancer is urgently needed. Apurinic/apyrimidinic endonuclease 1 (APE1) is a protein that has a DNA repair function and serves an important role in various physiological processes, including reduction-oxidation, cell proliferation and differentiation. The expression levels of APE1 are abnormally elevated in liver cancer cells, as ectopic expression of the APE1 gene has been reported, in addition to other abnormal signs, such as cell proliferation and migration. Therefore, it could be suggested that APE1 is an important indicator of hepatocellular carcinogenesis. APE1 may be used as a therapeutic target for tumors and proposed targeted therapy against abnormal APE1 expression could potentially inhibit the progression of tumors. The present review aimed to introduce the important role of APE1 in the physiological processes of tumor cells and the feasibility of using APE1 as a potential therapeutic target, providing a novel direction for the clinical treatment of liver cancer.
近年来，肝癌的发病率逐年上升。然而，目前肝癌的医学治疗方法有限，大多数患者术后复发风险较高。因此，迫切需要发现和开发新的肝癌治疗靶点。脱嘌呤/脱嘧啶内切酶1（APE1）是一种具有DNA修复功能的蛋白质，在包括氧化还原、细胞增殖和分化在内的各种生理过程中发挥重要作用。APE1的表达水平在肝癌细胞中异常升高，除了细胞增殖和迁移等其他异常迹象外，还报道了APE1基因的异位表达。因此，可以认为APE1是肝细胞癌变的一个重要指标。APE1可作为肿瘤的治疗靶点，针对APE1异常表达提出的靶向治疗可能会抑制肿瘤的进展。本综述旨在介绍APE1在肿瘤细胞生理过程中的重要作用以及将APE1用作潜在治疗靶点的可行性，为肝癌的临床治疗提供新的方向。
